Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity
10:19pm, Sunday, 08'th Feb 2026
Pfizer (PFE) remains a 'Hold' due to near-term headwinds, including a $1.5B patent cliff in 2026 and declining Covid-19 revenues. PFE's long-acting GLP-1 obesity program, bolstered by the Metsera acqu
3 High-Yield Dividend Stocks Perfect For Retirees
03:37pm, Friday, 06'th Feb 2026
What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks.
3 Healthcare Stocks Paying the Highest Dividends of 2026
03:15pm, Friday, 06'th Feb 2026
Despite an 8.2% forward yield, be careful with Perrigo, due to its value trap reputation. Yielding 6.7%, Pfizer is a strong choice among high-yield dividend stocks, given the company's post-COVID-19 c
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
02:55pm, Friday, 06'th Feb 2026
Pfizer made one thing clear this week: It's officially back in the obesity race.
Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
12:11pm, Friday, 06'th Feb 2026
PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.
5 High-Yield Stocks (6%-8%) Every Retiree Should Consider Now
07:45am, Friday, 06'th Feb 2026
Investors love dividend stocks, especially those with dependable, high yields, because they provide a substantial passive income stream and offer significant total return potential.
14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)
07:25am, Friday, 06'th Feb 2026
February's top Large Cap Value (GASV) stocks offer 27.69% to 69.77% net gains by February 2027, based on analyst targets. Fourteen of twenty-nine 'safer' lowest-priced GASV 'dogs' are currently buyabl
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics Li
Envestnet Asset Management Inc. Has $255.56 Million Stake in Pfizer Inc. $PFE
04:46am, Friday, 06'th Feb 2026
Envestnet Asset Management Inc. reduced its position in Pfizer Inc. (NYSE: PFE) by 10.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Ex
Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
07:09pm, Thursday, 05'th Feb 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting t
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
05:22pm, Thursday, 05'th Feb 2026
Pfizer Inc. NYSE: PFE helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report.
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?
03:45am, Thursday, 05'th Feb 2026
Pfizer hopes to differentiate itself in the obesity drug market with a once-monthly injection. The company plans to advance 20+ obesity therapy clinical studies in 2026.
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
11:20am, Wednesday, 04'th Feb 2026
Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of inn
Novo Nordisk: Pfizer weight loss drug offers credible new competition
08:45am, Wednesday, 04'th Feb 2026
Pfizer's monthly GLP-1 data prompts caution as new rival approaches Phase III Citi has reiterated its 'neutral' stance on Novo Nordisk (NYSE:NVO), warning that competition in the obesity drug market c
Will the Market Crash in 2026? Here's What History Says and What to Do About It
11:15pm, Tuesday, 03'rd Feb 2026
There are fears that stocks are overvalued right now, and some data backs this up. This could lead to a market crash, though we can't be certain.
